From Injections to Innovation - Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults and Children with Type 1 Diabetes
MWN-AI** Summary
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, has announced the upcoming presentation of results from its multinational randomized controlled trial named RADIANT. This trial evaluates the effectiveness of the Omnipod® 5 Automated Insulin Delivery (AID) System compared to traditional multiple daily injections (MDI) in managing Type 1 diabetes. Scheduled for presentation from March 19-22, 2025, at the International Conference on Advanced Technologies & Treatments for Diabetes in Amsterdam, the findings are significant because they mark the first assessment of direct transitions from MDI to AID in individuals who struggled to achieve optimal HbA1c levels.
The RADIANT study gathered participants aged 4 to 70 from France, the U.K., and Belgium, analyzing critical metrics such as HbA1c reduction and time spent in the target glucose range (TIR) while using the Omnipod 5 system alongside continuous glucose monitoring (CGM). Notably, it is the first trial to evaluate an AID system integrated with the Abbott FreeStyle Libre® 2 sensor.
During the conference, key experts will share insights at an Insulet-sponsored symposium titled “Transform Your Clinical Care with Omnipod 5: Revolutionizing Diabetes Management.” Presenting physicians will highlight transformative glycemic outcomes and user experiences associated with Omnipod 5. The symposium aims to inform clinical practices while showcasing the company's commitment to advancing diabetes management technologies.
Additionally, Insulet’s continued innovation will be highlighted through oral presentations and posters, discussing varied aspects of the Omnipod 5 system, including its performance in real-world settings. This approach aims to not only enhance patient care but also ensure sustainability and accessibility for broader populations managing diabetes. For more details, visit Insulet's website.
MWN-AI** Analysis
As Insulet Corporation (NASDAQ: PODD) prepares to share groundbreaking results from its RADIANT trial, investors should closely monitor the upcoming details and implications for the diabetes management market. Insulet, a leader in tubeless insulin pump technology, is set to present findings contrasting the efficacy of the Omnipod 5 with traditional multiple daily injections (MDI) at the ATTD conference in March 2025. This trial directly addresses the transition for patients who have struggled to reach glycemic goals with MDI, showcasing both the potential of automated insulin delivery (AID) systems and improvements in user experience, particularly for children and adults.
The trial’s results, especially in terms of lowering HbA1c and increasing time in target glucose ranges, could affirm Insulet's competitive edge within a growing market for diabetes technologies. With an increasing prevalence of type 1 diabetes, the focus on innovative and user-friendly treatment options like the Omnipod 5 positions Insulet favorably against competitors. The integration of the device with Abbott's FreeStyle Libre 2 sensor also underscores a move towards comprehensive diabetes management solutions, which may entice healthcare providers and patients alike.
Investors should consider the broader implications of these results on Insulet’s market share and stock valuation. Furthermore, Insulet's ongoing commitment to innovative therapies and its presentation of multiple clinical findings at ATTD could drive interest among healthcare professionals and patients, subsequently boosting brand loyalty and sales.
Given the anticipated positive reception of the Omnipod 5, alongside its current and future developments, it may be prudent to accumulate shares for long-term growth in a sector increasingly leaning towards technology-driven healthcare solutions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced the Company will present results from its multinational Randomized Controlled Trial to Demonstrate the Efficacy of Omnipod 5 Compared with Multiple Daily Injections for Treatment of Type 1 Diabetes (RADIANT). The results will be shared at the 18 th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) taking place March 19 – 22, 2025 in Amsterdam, the Netherlands, and online.
The study assessed changes in HbA1c as well as time in target glucose range (TIR) for people aged 4 to 70 years living with type 1 diabetes in France, the U.K., and Belgium using Omnipod 5, compared with those using multiple daily injections (MDI) with a continuous glucose monitor (CGM). RADIANT is the first randomized controlled trial to assess the direct transition from MDI to an automated insulin delivery (AID) system in adults and children who were not previously achieving clinical targets for HbA1c with MDI. It is also the first randomized clinical trial to assess the safety and efficacy of an AID system paired with an Abbott FreeStyle Libre ® 2 family sensor.
The RADIANT results will be discussed at an Insulet-sponsored symposium, “Transform Your Clinical Care with Omnipod 5: Revolutionizing Diabetes Management,” being held on Wednesday, March 19 from 2:40 p.m. – 4:10 p.m. CET in Hall E.
The symposium will be presented by:
- Dr. Emma Wilmot, PhD, FRCP, Associate Professor, University of Nottingham, School of Medicine, Nottingham, U.K. – Omnipod 5 Delivers Transformative Glycemic Outcomes – Sharing the Latest Breaking Results
- Dr. Chantal Mathieu, MD, PhD, Professor of Medicine, Katholieke Universiteit Leuven, Belgium – How Omnipod 5 is Providing an Unparalleled User Experience
- Dr. Brynn Marks, MD, MSHPEd, Director of Technology and Attending Physician, Children’s Hospital of Philadelphia, Assistant Professor, CE Perelman School of Medicine of the University of Pennsylvania, U.S. – Accelerating AID for All – Reaching the Broadest Populations Effectively
- Dr. Trang Ly, MBBS, FRACP, PhD, Insulet Senior Vice President and Chief Medical Officer, will provide a Company update on future innovations at the symposium
Additionally, Dr. Wilmot will be conducting an oral presentation about RADIANT on Saturday, March 22, from 10:50 a.m. – 11:00 a.m. A total of 11 presentations and posters on the Omnipod 5 AID System and the Omnipod DASH ® Insulin Management System will be presented at ATTD (all times CET) :
Oral Presentations
Thursday, March 20
Oral Presentation SO031 (4:15 p.m. – 4:20 p.m., Station 04, Session 09) – How Do Outcomes with the Omnipod 5 Automated Insulin Delivery (AID) System Compare for Persons with Type 1 Versus Type 2 Diabetes? Learnings Across Studies with Dr. Viral Shah
Oral Presentation SO034 (4:30 p.m. – 4:35 p.m., Station 04, Session 09) – Simplified Meal Bolus Strategies for the Omnipod 5 Automated Insulin Delivery (AID) System in People with Type 2 Diabetes (T2D): Sub-Analysis of the SECURE-T2D Study with Dr. Georgia Davis
Friday, March 21
Oral Presentation SO058 (4:50 p.m. – 4:55 p.m., Station 02, Session 16) – Real-World HbA1c Following Initiation of the Omnipod 5 Automated Insulin Delivery System with Dr. Carol Levy
Oral Presentation SO060 (5:00 p.m. – 5:05 p.m., Station 02, Session 16) – Real-World Glycemic Outcomes of >19,100 Adults with Type 2 Diabetes (T2D) Using the Omnipod 5 Automated Insulin Delivery (AID) System with Cloud-Based Data Management with Dr. Eden Miller
Saturday, March 22
Oral Presentation OP046 (10:50 a.m. – 11:00 a.m., Hall D1, Session 06) – Efficacy of the Omnipod 5 Automated Insulin Delivery (AID) System Compared with Multiple Daily Injections in Type 1 Diabetes: A Multinational Randomized Controlled Trial (RADIANT) with Dr. Emma Wilmot
Oral Presentation OP056 (11:30 a.m. – 11:40 a.m., Hall D1, Session 08) – Impact of Lowering Target Glucose Setting with the Omnipod 5 Automated Insulin Delivery (AID) System: Evidence from Real-World Use with Dr. Gregory Forlenza
Oral Presentation OP087 (1:45 p.m. – 1:55 p.m., Hall E, Session 13) – Improved Glycemic Outcomes with the Omnipod 5 System in People with Type 2 Diabetes Using GLP 1 – Receptor Agonists or SGLT2 Inhibitors: Sub-Analysis of the SECURE-T2D Study with Davida Kruger, NP
Poster Presentations
e-Poster PV076 – Real-World Performance of the Omnipod 5 Automated Insulin Delivery (AID) System in Adults with Type 1 Diabetes in the United Kingdom and Germany with Dr. Jackie Elliott
e-Poster PV062 – Real-World Performance of the Omnipod 5 Automated Insulin Delivery (AID) System in Children and Adolescents with Type 1 Diabetes in the United Kingdom and Germany with Dr. Torben Biester
e-Poster PV328 – Real-World Data of 13,827 French T1D Users of the Omnipod DASH Insulin Management System From a Cloud-Based Data Management Platform with Pr. Nathalie Jeandidier
e-Poster PV329 – Real-World Data of 934 French T2D Users of the Omnipod DASH Insulin Management System From a Cloud-Based Data Management Platform with Pr. Nathalie Jeandidier
Additional Exhibit Hall Activities and Programs
In the exhibition hall, delegates can look forward to a variety of interactive experiences at the Omnipod booth, showcasing how Omnipod 5 is transforming lives globally. Delivering the latest insights and learnings to audiences worldwide, attendees will have the unique opportunity to attend live recordings of the increasingly popular podcasts, Within Range: Demystifying Diabetes Tech , and the podcast specially curated for people living with diabetes, TypeCast: Life Between the Lines .
There will also be a Baird hosted webcast, “Takeaways with Dr. Trang Ly”, that recaps the highlights, new clinical data, and updates from ATTD. This will take place on Friday, March 21, 4:00 p.m. from Insulet’s exhibition booth. A link to the webcast will be available on the Investor Relations section of the Company's website at investors.insulet.com , under “Events and Presentations,” and will be archived for future replay.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: insulet.com and omnipod.com .
©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250316052311/en/
Investor Relations:
June Lazaroff
Senior Director, Investor Relations
(978) 600-7717
jlazaroff@insulet.com
Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com
FAQ**
What insights can we expect from the RADIANT trial results presented at ATTD regarding the efficacy of Insulet Corporation PODD's Omnipod 5 compared to multiple daily injections for type 1 diabetes management?
How does Insulet Corporation PODD plan to leverage the findings from the RADIANT trial to enhance its market positioning in the automated insulin delivery system sector following the ATTD conference?
What potential implications do the findings from the RADIANT trial have for health care providers and patients using Insulet Corporation PODD's Omnipod 5 in terms of achieving glycemic targets?
In what ways could the discussions and presentations at ATTD influence future innovations within Insulet Corporation PODD, particularly in expanding the use of the Omnipod technology platform?
**MWN-AI FAQ is based on asking OpenAI questions about Insulet Corporation (NASDAQ: PODD).
NASDAQ: PODD
PODD Trading
-7.26% G/L:
$217.82 Last:
933,644 Volume:
$226.138 Open:
